» Articles » PMID: 34125982

Giant Cell Tumor of Bone - Analysis of 213 Cases Involving Extra-craniofacial Bones

Abstract

We elucidated clinicopathological characteristics of giant cell tumor of bone (GCTB) in Japan, and significant clinicopathological factors for predicting local recurrence. Clinicopathological profiles of 213 patients with GCTB (100 male, 113 female) involving extra-craniofacial bones were retrieved. Pathological slides obtained at the initial surgery were reviewed. Fourteen pathological and five clinical features were statistically analyzed to disclose prognostic significance. Patient age ranged from 12-80 years (Average 38.7). Long bones were most frequently affected (86.4%), especially around the knee (62.9%). Histological features are basically similar to those previously reported. Within a follow-up period (24-316 months, average 106.1 months), the local recurrence rate is 29.1%. Metastasis has occurred in 9 patients. Cox regression analysis of representative clinicopathological features shows that younger age, higher mitotic count, smaller zones of stromal hemorrhage, considerable vascular invasion and absence of ischemic necrosis are significant predictors for local recurrence. Initial operative method (curettage) is a significant risk factor in univariate analysis but not by multivariate analysis (P = 0.053). Denosumab administration increases risk but not significantly (P = 0.053). Histone 3.3 G34W immunopositivity is not significant for predicting local recurrence.

Citing Articles

Comparative analysis of aggressiveness in giant cell tumor of bone between upper and lower extremities: A systematic review and meta-analysis.

Saputra R, Kusuma D, Kaldani F, Fahmi K J Bone Oncol. 2025; 51:100663.

PMID: 40028631 PMC: 11871493. DOI: 10.1016/j.jbo.2025.100663.


Secondary Malignancy in Giant Cell Tumor: A Single-Center Study.

Joo M, Lee Y, Park H, Chung Y, Yoon C Curr Oncol. 2022; 29(6):4068-4080.

PMID: 35735433 PMC: 9221612. DOI: 10.3390/curroncol29060324.


Single-cell RNA sequencing reveals differential expression of EGFL7 and VEGF in giant-cell tumor of bone and osteosarcoma.

Feleke M, Feng W, Song D, Li H, Rothzerg E, Wei Q Exp Biol Med (Maywood). 2022; 247(14):1214-1227.

PMID: 35695550 PMC: 9379604. DOI: 10.1177/15353702221088238.


Giant cell tumor of bone - Analysis of 213 cases involving extra-craniofacial bones.

Konishi E, Outani H, Mano M, Nagata S, Shirai T, Naka N Pathol Int. 2021; 71(8):500-511.

PMID: 34125982 PMC: 8453959. DOI: 10.1111/pin.13107.

References
1.
Masui F, Ushigome S, Fujii K . Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int. 1998; 48(9):723-9. DOI: 10.1111/j.1440-1827.1998.tb03973.x. View

2.
Prosser G, Baloch K, Tillman R, Carter S, Grimer R . Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?. Clin Orthop Relat Res. 2005; (435):211-8. DOI: 10.1097/01.blo.0000160024.06739.ff. View

3.
Bertoni F, Present D, Sudanese A, Baldini N, Bacchini P, Campanacci M . Giant-cell tumor of bone with pulmonary metastases. Six case reports and a review of the literature. Clin Orthop Relat Res. 1988; (237):275-85. View

4.
Rock M, Pritchard D, Unni K . Metastases from histologically benign giant-cell tumor of bone. J Bone Joint Surg Am. 1984; 66(2):269-74. View

5.
Scoccianti G, Totti F, Scorianz M, Baldi G, Roselli G, Beltrami G . Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?. Clin Orthop Relat Res. 2019; 476(9):1783-1790. PMC: 6259811. DOI: 10.1007/s11999.0000000000000104. View